Category: GLP-1 Agonist Medications

Weight loss medications, structured diet plans, and lifestyle programs are helping more Canadians reduce excess weight than ever before. Newer options — including GLP-1 medications — have changed how obesity and metabolic health are managed. But there is an important clinical detail many people don’t realize:

(more…)

Recent announcements from U.S. regulators have brought important clarity to patients using — or considering — popular GLP-1 weight-loss medications such as Wegovy, Saxenda, and Zepbound.

(more…)

GLP-1 receptor agonists—such as Ozempic (semaglutide) and tirzepatide—represent a true therapeutic breakthrough in the fight against obesity and type 2 diabetes. Their benefits, including significant weight loss and protection against comorbidities like cardiovascular disease, are well-documented. However, as independent data from studies in the US and Canada shows, the biggest challenge lies not in the drug’s effectiveness, but in patient adherence.

(more…)

In Part 1 of our series, we explained how insurers are limiting pharmacy choice through patient steering. Now, let’s look at a real-world example: patients prescribed GLP-1 medications (such as Ozempic, Wegovy, or Mounjaro) for diabetes or weight management.

(more…)

As specialists in diabetes care and medication management, pharmacists at Centrum Pharmacy are often asked about the safety profile of glucagon‑like peptide‑1 (GLP‑1) receptor agonists—particularly concerns about pancreatitis and pancreatic cancer. A new population‑based cohort study brings reassuring news: long‑term use of GLP‑1 receptor agonists does not appear to increase the risk of pancreatic cancer.

(more…)

Alzheimer’s disease is one of the most pressing health challenges of our time, affecting millions of families worldwide. While research into treatments continues, an unexpected group of medications is drawing global attention: GLP-1 receptor agonists, the same drugs that revolutionized diabetes and weight management.

(more…)

With the catchy ads and constant social media chatter, it’s hard to avoid the buzz around GLP-1 medications like Ozempic. Originally intended for managing Type 2 diabetes, these drugs have become increasingly popular for weight loss, creating a whirlwind of ethical debates and a frustrating shortage for those who need them most. While it’s easy to get swept up in the “I just asked” trend, it’s crucial to look beyond the convenience and examine the quality of care being provided.

(more…)

In recent months, we’ve seen a troubling spike in fake diabetes products being promoted on social media platforms and online. These scams—ranging from counterfeit smartwatches that claim to non-invasively measure blood sugar to unauthorized oral drops mimicking GLP-1 medications—pose serious health risks for people living with diabetes.

(more…)

With the rising popularity of prescription weight loss medications like Ozempic and Mounjaro—and their high cost—many people are turning to online “miracle” alternatives. But beware: these products are often scams, loaded with false claims, hidden ingredients, and risky billing schemes.

(more…)

If you’ve been following the headlines, you may have seen the buzz around Novo Nordisk and the Canadian patent for Ozempic (semaglutide).

You may have heard the buzz: Novo Nordisk’s Ozempic patent in Canada has expired — not because of science, but because of a $450 missed fee. (Yes, really.)

(more…)